PMID- 30417460 OWN - NLM STAT- MEDLINE DCOM- 20190520 LR - 20200825 IS - 1750-3639 (Electronic) IS - 1015-6305 (Print) IS - 1015-6305 (Linking) VI - 29 IP - 1 DP - 2019 Jan TI - Clinicopathologic features of anaplastic myxopapillary ependymomas. PG - 75-84 LID - 10.1111/bpa.12673 [doi] AB - Myxopapillary ependymomas (MPE) are considered benign (World Health Organization (WHO) grade I) neoplasms with favorable prognosis. However, malignant behavior occurs in a small subset. To our knowledge, only five anaplastic MPEs have been reported without consensus on diagnostic criteria. We retrieved 14 anaplastic MPEs from the pathology archives of six institutions. Each tumor included at least two of the following features: >/=5 mitoses per 10 high power fields, Ki-67 labeling index (LI) >/=10%, microvascular proliferation (MVP) and spontaneous necrosis. These features were typically encountered in the foci of hypercellularity and reduced mucin. There were eight male and six female patients (age range 6-57 years, median = 16.5). Ten tumors displayed anaplasia at initial resection, and 4 were anaplastic at a second surgery for recurrence (ranging from 9 months to 14 years following initial resection). The Ki-67 LI ranged between 8% and 40% in the anaplastic foci and <3% in the foci of classic MPE. There was documented cerebrospinal fluid (CSF) dissemination in seven cases, recurrence following an anaplastic diagnosis in three cases and bone or soft tissue invasion in two cases. One patient suffered lung metastases. Two cases evaluated by targeted next-generation sequencing and one evaluated by fluorescence in situ hybridization (FISH) showed nonspecific chromosomal gains. We conclude that although rare, anaplastic MPE occurs in both pediatric and adult patients, similar to other ependymomas. At a minimum, closer follow-up is recommended, given the concern for aggressive biologic potential. Further study is needed to determine WHO grading criteria and genetic indicators of tumor progression. CI - (c) 2018 International Society of Neuropathology. FAU - Lee, Julieann C AU - Lee JC AUID- ORCID: 0000-0003-0138-4862 AD - Department of Pathology, University of California, San Francisco, CA. FAU - Sharifai, Nima AU - Sharifai N AD - Division of Neuropathology, Department of Pathology and Immunology, Washington University, St. Louis, MO. FAU - Dahiya, Sonika AU - Dahiya S AD - Division of Neuropathology, Department of Pathology and Immunology, Washington University, St. Louis, MO. FAU - Kleinschmidt-DeMasters, Bette K AU - Kleinschmidt-DeMasters BK AUID- ORCID: 0000-0002-4471-1678 AD - Department of Pathology, University of Colorado, Denver, CO. FAU - Rosenblum, Marc K AU - Rosenblum MK AD - Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY. FAU - Reis, Gerald F AU - Reis GF AD - Department of Pathology, Memorial Healthcare System, Hollywood, FL. FAU - Samuel, David AU - Samuel D AD - Neuro-oncology, Valley Children's Hospital, Madera, CA. FAU - Siongco, Aleli M AU - Siongco AM AD - Department of Pathology, Valley Children's Hospital, Madera, CA. FAU - Santi, Mariarita AU - Santi M AD - Department of Pathology, The Children's Hospital of Philadelphia, University of Pennsylvania, Philadelphia, PA. FAU - Storm, Phillip B AU - Storm PB AD - Division of Neurosurgery, The Children's Hospital of Philadelphia, Philadelphia, PA. FAU - Ferris, Sean P AU - Ferris SP AD - Department of Pathology, University of California, San Francisco, CA. FAU - Bollen, Andrew W AU - Bollen AW AD - Department of Pathology, University of California, San Francisco, CA. FAU - Pekmezci, Melike AU - Pekmezci M AD - Department of Pathology, University of California, San Francisco, CA. FAU - Solomon, David A AU - Solomon DA AUID- ORCID: 0000-0003-4571-7999 AD - Department of Pathology, University of California, San Francisco, CA. AD - Clinical Cancer Genomics Laboratory, University of California, San Francisco, CA. FAU - Tihan, Tarik AU - Tihan T AD - Department of Pathology, University of California, San Francisco, CA. FAU - Perry, Arie AU - Perry A AUID- ORCID: 0000-0002-8300-7261 AD - Department of Pathology, University of California, San Francisco, CA. LA - eng GR - P30 CA008748/CA/NCI NIH HHS/United States PT - Journal Article PL - Switzerland TA - Brain Pathol JT - Brain pathology (Zurich, Switzerland) JID - 9216781 RN - 0 (Antigens, Nuclear) RN - 0 (Ki-67 Antigen) SB - IM MH - Adolescent MH - Adult MH - Antigens, Nuclear MH - Child MH - Ependymoma/*diagnosis/*pathology MH - Female MH - Humans MH - In Situ Hybridization, Fluorescence MH - Ki-67 Antigen MH - Male MH - Middle Aged MH - Neoplasm Recurrence, Local/pathology MH - Spinal Cord Neoplasms/*pathology PMC - PMC7444646 MID - NIHMS1619450 OTO - NOTNLM OT - CSF dissemination OT - anaplastic transformation OT - malignant neoplasm OT - metastasis OT - microvascular proliferation OT - myxopapillary ependymoma OT - necrosis OT - recurrence EDAT- 2018/11/13 06:00 MHDA- 2019/05/21 06:00 PMCR- 2019/01/01 CRDT- 2018/11/13 06:00 PHST- 2018/09/08 00:00 [received] PHST- 2018/10/29 00:00 [accepted] PHST- 2018/11/13 06:00 [pubmed] PHST- 2019/05/21 06:00 [medline] PHST- 2018/11/13 06:00 [entrez] PHST- 2019/01/01 00:00 [pmc-release] AID - BPA12673 [pii] AID - 10.1111/bpa.12673 [doi] PST - ppublish SO - Brain Pathol. 2019 Jan;29(1):75-84. doi: 10.1111/bpa.12673.